Saturday 17 October 2026
Export NTBLQ’s income statement to Excel — free account
Notable Labs, Ltd.
NTBLQ Healthcare Biotechnology
Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow NTBLQ
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 3 | 2 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(6.73) | (25.53) | (0.78) | (4.41) | (4.58) | (2.04) | 8.96 | — |
P/S ratio |
759.69 | 387.86 | 170.36 | 89.60 | 76.69 | 54.72 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(10.91) | (57.54) | (8.00) | (15.22) | (9.78) | (0.06) | 1.64 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | (0.09) | (2.79) | 33.26 | (4.77) | — | — |
P/Operating CF |
(1.00) | 0.23 | (19.72) | (12.03) | (10.67) | (10.68) | 18.92 | — |
P/B ratio |
0.40 | 0.00 | 2.59 | 2.67 | 1.20 | 0.60 | 3.53 | — |
Price to Tangible BV |
0.40 | 0.00 | 2.59 | 2.67 | 1.20 | 0.60 | 3.53 | — |
EV/Sales |
(685.56) | 363.86 | 103.52 | 58.74 | 11.86 | (30.81) | 0.00 | — |
EV/EBITDA |
0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.90 | 0.00 | — |
EV/Operating CF |
0.40 | (0.25) | (3.18) | (2.32) | (0.51) | 1.15 | (37.36) | — |
EV/FCF |
0.40 | (0.25) | (3.01) | (2.31) | (0.51) | 1.01 | (13.85) | — |
Quick Ratio |
4.32 | 0.79 | 5.35 | 4.10 | 4.29 | 10.63 | 7.49 | 9.61 |
Current Ratio |
5.65 | 1.48 | 5.53 | 4.29 | 4.36 | 10.83 | 7.72 | 9.73 |
Net Debt/EBITDA |
0.80 | 0.13 | 1.79 | 1.22 | 1.93 | 2.50 | 5.21 | 2.80 |
Debt/Assets |
1.35% | 0.00% | 2.82% | 4.87% | 0.20% | 0.74% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.00 | 0.04 | 0.07 | 0.00 | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 | 0.25 | 0.00 |
Operating CF/Net income |
1.22 | 0.81 | 0.84 | 0.97 | 0.67 | 0.77 | 0.38 | 0.84 |
Capex/Depreciation |
(0.25) | 0.17 | (1.17) | (0.04) | (0.06) | (1.92) | (41.55) | (3.78) |
Interest Coverage |
— | (152.05) | (681.73) | (233.17) | (23.08) | (23.36) | (31.81) | (61.88) |
| 103.08% | (211.68%) | (73.43%) | (72.38%) | (43.53%) | (37.54%) | (20.63%) | (41.35%) | |
| (89.92%) | (41.06%) | (56.26%) | (53.41%) | (35.37%) | (32.38%) | (17.95%) | (36.99%) | |
ROIC |
(257.90%) | 0.00% | 0.00% | (611.83%) | 0.00% | (433.15%) | (568.69%) | 0.00% |
Return on Tangible Assets |
(86.33%) | (1,017.44%) | (57.80%) | (77.73%) | (52.58%) | (36.63%) | (17.47%) | (37.68%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 51.07 | 408.51 | 179.07 | 52.65 | 0.00 |
Research and Development Expense of Revenue |
1,518.06% | 97,200.00% | 2,955.08% | 2,131.89% | 2,618.15% | 2,724.79% | 128.17% | 0.00% |
Selling, General and Administrative Expense of Revenue |
3,246.45% | 64,450.00% | 1,003.13% | 580.80% | 1,015.66% | 960.17% | 46.23% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
190.00% | 7,262.50% | 256.25% | 180.15% | 400.53% | 661.03% | 29.95% | 0.00% |
Graham Net Nets |
1.82 | (12.73) | 0.31 | 0.26 | 0.58 | 1.38 | 0.25 | — |
Graham Number |
0.00 | 136.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(185.53%) | (310.47%) | (22.82%) | (29.60%) | (45.79%) | (63.85%) | (5.13%) | — |
Free Cash Flow Yield |
(226.75%) | (373.46%) | (20.22%) | (28.36%) | (30.54%) | (55.93%) | (5.22%) | — |
Revenue per Share |
0.09 | 0.01 | 0.40 | 0.74 | 0.55 | 0.62 | 17.69 | 0.00 |
Operating CF per Share |
(4.15) | (17.75) | (13.17) | (18.72) | (12.75) | (16.63) | (4.88) | (18.78) |
Capex per Share |
(0.02) | 0.08 | (0.77) | (0.04) | (0.07) | (2.36) | (8.27) | (0.69) |
Free Cash Flow per Share |
(4.17) | (17.66) | (13.94) | (18.76) | (12.83) | (18.99) | (13.15) | (19.47) |
Cash per Share |
3.58 | 2.41 | 28.01 | 24.38 | 35.60 | 53.54 | 69.84 | 63.36 |
Shareholders Equity per Share |
4.58 | (56.35) | 26.66 | 24.76 | 35.10 | 56.31 | 71.34 | 59.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.58 | (56.35) | 26.66 | 24.76 | 35.10 | 56.31 | 71.34 | 59.37 |
Free Cash Flow |
(13.78) | (11.59) | (26.45) | (23.43) | (13.16) | (17.90) | (10.30) | (13.90) |
Working Capital |
12.73 | 0.97 | 44.92 | 24.53 | 29.11 | 46.94 | 50.89 | 41.79 |
Capital Expenditures |
(0.06) | 0.05 | (1.46) | (0.05) | (0.07) | (2.22) | (6.48) | (0.49) |
Net Current Asset Value |
11.04 | (39.49) | 40.77 | 21.20 | 24.80 | 44.12 | 48.67 | 41.70 |
EV/EBIT |
0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.85 | 0.00 | — |
Capex to Sales |
0.21 | (6.75) | 1.91 | 0.06 | 0.13 | 3.80 | 0.47 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.81 | 0.73 | 0.18 | 0.18 | 0.16 | 0.13 | 0.02 | 0.19 |
Cash ROIC |
(50.66%) | 32.75% | (25.06%) | (36.96%) | (18.12%) | (17.21%) | (9.31%) | (15.86%) |
Accounts Receivable Turnover |
0.00 | 0.03 | 2.59 | 2.43 | 1.23 | 0.51 | 10.02 | 0.00 |
Accounts Payable Turnover |
0.15 | 0.02 | 0.05 | 0.06 | 0.04 | 0.04 | 0.06 | 0.03 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
3,329.47 | 2,853.32 | 8,739.00 | 5,776.08 | 12,340.95 | 6,425.55 | 7,002.63 | 13,443.23 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.28 | 0.30 | 0.38 | 0.46 | 1.14 | 1.38 | 2.06 |
Average Payables |
1.31 | 4.78 | 7.49 | 6.87 | 5.82 | 5.33 | 5.66 | 4.47 |
Average Assets |
12.53 | 35.09 | 53.18 | 45.36 | 54.84 | 63.18 | 56.48 | 43.26 |
Average Common Equity |
(10.93) | 6.81 | 40.75 | 33.47 | 44.56 | 54.50 | 49.15 | 38.70 |
Columns are period end dates